OKUR (OnKure Therapeutics) Beginning Cash Position: $192.11 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OKUR OnKure Therapeutics Inc OKUR
14 GF Score
Price $4.13
! 2 Warning Signs
View Full Analysis

What is OnKure Therapeutics Beginning Cash Position?

OnKure Therapeutics OKUR -0.12% 14 Beginning Cash Position is $192.11 Mil as of Jun. 2026. GuruFocus rates OKUR with a GF Score™ of 14/100. The stock has 2 warning signs investors should review.

OnKure Therapeutics's Beginning Cash Position for the quarter that ended in Jun. 2026 was $192.11 Mil.

OnKure Therapeutics's quarterly Beginning Cash Position declined from Dec. 2025 ($70.57 Mil) to Mar. 2026 ($59.05 Mil) but then increased from Mar. 2026 ($59.05 Mil) to Jun. 2026 ($192.11 Mil).

OnKure Therapeutics's annual Beginning Cash Position increased from Dec. 2023 ($11.54 Mil) to Dec. 2024 ($29.88 Mil) and increased from Dec. 2024 ($29.88 Mil) to Dec. 2025 ($110.76 Mil).

OnKure Therapeutics Beginning Cash Position Related Terms

OnKure Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for OnKure Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OnKure Therapeutics Beginning Cash Position Chart

OnKure Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
13.17 11.54 29.88 110.76

OnKure Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 96.66 83.37 70.57 59.05 192.11
OKUR
14GF Score
OnKure Therapeutics Inc OKUR
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OnKure Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $192.11 Mil mean?
OnKure Therapeutics (OKUR) has a Beginning Cash Position of $192.11 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on OnKure Therapeutics and its competitors.
Is OnKure Therapeutics' Beginning Cash Position too high?
OnKure Therapeutics' current Beginning Cash Position is $192.11 Mil. Overall, OnKure Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does OnKure Therapeutics' Beginning Cash Position compare to CRBP and HUMA?
OnKure Therapeutics' Beginning Cash Position of $192.11 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on OnKure Therapeutics and its competitors. OnKure Therapeutics's current Beginning Cash Position is $192.11 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OnKure Therapeutics stock overvalued right now?
OnKure Therapeutics (OKUR) has a current Beginning Cash Position of $192.11 Mil. The current Beginning Cash Position is $192.11 Mil. OnKure Therapeutics' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For OnKure Therapeutics (OKUR), the current Beginning Cash Position is $192.11 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OnKure Therapeutics Business Description

Address 6707 Winchester Circle, Suite 400, Boulder, CO, USA, 80301
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3K?. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.
14GF Score

Get the complete analysis for OKUR

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.13
Price